Strategic Initiative

Slingshot members are tracking this corporate initiative:

Novartis (NVS) Out-Licenses U.S Rights to Three Treatments for Chronic Obstructive Pulmonary Disease (COPD) to Sunovion Pharmaceuticals

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Sunovion Pharmaceuticals

Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Dec 21, 2016
Projected Implementation:
Q1, 2017
Relevance Tracked Until:
Q1, 2018
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords U.s Rights, Three Treatments, Chronic Obstructive Pulmonary Disease, Copd, Utibron Neohaler, Seebri Neohaler, Arcapta Neohaler